(BMRN) Biomarin Pharmaceutical - Overview
Stock: Enzyme Replacement, Growth Modulator, Gene Therapy, Small Molecule
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 30.6% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.23 |
| Alpha | -22.05 |
| Character TTM | |
|---|---|
| Beta | 0.737 |
| Beta Downside | 0.913 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.99% |
| CAGR/Max DD | -0.36 |
Description: BMRN Biomarin Pharmaceutical January 02, 2026
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a U.S.-based biotech that focuses on developing and commercializing therapies for rare, life-threatening diseases across North America, Europe, Latin America, the Middle East, and the Asia-Pacific.
The firm’s marketed portfolio includes VIMIZIM (MPS IV A), VOXZOGO (achondroplasia), NAGLAZYME (MPS VI), PALYNZIQ (phenylketonuria), BRINEURA (Batten disease), ALDURAZYME (MPS I), KUVAN (PKU), and ROCTAVIAN (severe hemophilia A). Its pipeline features BMN 333 (long-acting CNP for growth disorders), BMN 349 (oral therapy for α1-antitrypsin deficiency-related liver disease), and BMN 351 (antisense oligonucleotide for Duchenne muscular dystrophy).
In 2023 BioMarin generated approximately $2.1 billion in revenue, with VIMIZIM and VOXZOGO together accounting for roughly 45 % of sales, while the company posted a net loss of $215 million, reflecting high R&D spend and amortization of acquisition-related intangibles. The rare-disease sector is currently benefitting from favorable orphan-drug pricing policies and a CAGR of ~10 % in global orphan-drug sales, but it also faces increasing payer scrutiny on price sustainability.
For analysts looking to deepen their quantitative assessment, the ValueRay platform offers a consolidated view of BioMarin’s valuation metrics and peer-group benchmarks that can help surface any pricing anomalies.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 182.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 6.53 > 1.0 |
| NWC/Revenue: -10.6k% < 20% (prev 85.04%; Δ -10.7k% < -1%) |
| CFO/TA 0.12 > 3% & CFO 914.0m > Net Income 182.5m |
| Net Debt (-638.9m) to EBITDA (200.8m): -3.18 < 3 |
| Current Ratio: 4.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (191.6m) vs 12m ago -2.79% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: -0.40% > 50% (prev 40.18%; Δ -40.58% > 0%) |
| Interest Coverage Ratio: -97.8k > 6 (EBITDA TTM 200.8m / Interest Expense TTM -2000 ) |
Altman Z'' 3.01
| A: 0.40 (Total Current Assets 3.85b - Total Current Liabilities 798.4m) / Total Assets 7.61b |
| B: 0.03 (Retained Earnings 200.8m / Total Assets 7.61b) |
| C: 0.03 (EBIT TTM 195.6m / Avg Total Assets 7.23b) |
| D: 0.10 (Book Value of Equity 155.7m / Total Liabilities 1.56b) |
| Altman-Z'' Score: 3.01 = A |
What is the price of BMRN shares?
Over the past week, the price has changed by +2.81%, over one month by -3.23%, over three months by +12.13% and over the past year by -9.65%.
Is BMRN a buy, sell or hold?
- StrongBuy: 16
- Buy: 7
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BMRN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 90.7 | 56.1% |
| Analysts Target Price | 90.7 | 56.1% |
| ValueRay Target Price | 57.6 | -0.9% |
BMRN Fundamental Data Overview February 05, 2026
P/E Forward = 11.0375
P/S = 3.5772
P/B = 1.8273
P/EG = 0.4432
Revenue TTM = -28.8m USD
EBIT TTM = 195.6m USD
EBITDA TTM = 200.8m USD
Long Term Debt = 596.7m USD (from longTermDebt, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, last quarter)
Debt = 604.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -638.9m USD (from netDebt column, last quarter)
Enterprise Value = 10.19b USD (11.07b + Debt 604.2m - CCE 1.48b)
Interest Coverage Ratio = -97.8k (Ebit TTM 195.6m / Interest Expense TTM -2000 )
EV/FCF = 12.26x (Enterprise Value 10.19b / FCF TTM 831.4m)
FCF Yield = 8.16% (FCF TTM 831.4m / Enterprise Value 10.19b)
WARNING: Negative Revenue TTM = -28.8m
FCF Margin = -2885 % (FCF TTM 831.4m / Revenue TTM -28.8m)
WARNING: Negative Revenue TTM = -28.8m
Net Margin = -633.1% (Net Income TTM 182.5m / Revenue TTM -28.8m)
WARNING: Negative Revenue TTM = -28.8m
Gross Margin = unknown ((Revenue TTM -28.8m - Cost of Revenue TTM -3.95m) / Revenue TTM)
Tobins Q-Ratio = 1.34 (Enterprise Value 10.19b / Total Assets 7.61b)
Interest Expense / Debt = -1.34% (Interest Expense -8.12m / Debt 604.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = 154.6m (EBIT 195.6m * (1 - 21.00%))
Current Ratio = 4.83 (Total Current Assets 3.85b / Total Current Liabilities 798.4m)
Debt / Equity = 0.10 (Debt 604.2m / totalStockholderEquity, last quarter 6.06b)
Debt / EBITDA = -3.18 (Net Debt -638.9m / EBITDA 200.8m)
Debt / FCF = -0.77 (Net Debt -638.9m / FCF TTM 831.4m)
Total Stockholder Equity = 5.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.52% (Net Income 182.5m / Total Assets 7.61b)
RoE = 3.10% (Net Income TTM 182.5m / Total Stockholder Equity 5.88b)
RoCE = 3.02% (EBIT 195.6m / Capital Employed (Equity 5.88b + L.T.Debt 596.7m))
RoIC = 2.39% (NOPAT 154.6m / Invested Capital 6.48b)
WACC = 8.13% (E(11.07b)/V(11.67b) * Re(8.63%) + D(604.2m)/V(11.67b) * Rd(-1.34%) * (1-Tc(0.21)))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.05%
[DCF Debug] Terminal Value 80.84% ; FCFF base≈619.2m ; Y1≈763.8m ; Y5≈1.30b
Fair Price DCF = 114.8 (EV 21.43b - Net Debt -638.9m = Equity 22.06b / Shares 192.1m; r=8.13% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 49.37 | EPS CAGR: -30.01% | SUE: -2.06 | # QB: 0
Revenue Correlation: -39.95 | Revenue CAGR: -66.37% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.31 | Chg30d=+0.046 | Revisions Net=+1 | Analysts=13
EPS next Year (2026-12-31): EPS=5.21 | Chg30d=-0.095 | Revisions Net=+1 | Growth EPS=+54.6% | Growth Revenue=+7.0%